Beaulieu, Alexis
4 papers on CoChat
Most cited papers
- Verified
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Buteau, J. P., Martin, A. J., Emmett, L., Iravani, A., Sandhu, S., Joshua, A. M., Francis, R. J., Zhang, A. Y., Scott, A. M., Lee, S.-T., et al. (2022) · The Lancet Oncology
Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research
Cited by 296
- Verified
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177 Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine
Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research
Cited by 292
- Verified
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Buteau, J. P., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., et al. (2024) · The Lancet Oncology
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 230
- Verified
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging
Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications
Cited by 184
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free